Cargando…
SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1(+) myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 8...
Autores principales: | Ostendorf, Lennard, Dittert, Philipp, Biesen, Robert, Duchow, Ankelien, Stiglbauer, Victoria, Ruprecht, Klemens, Bellmann-Strobl, Judith, Seelow, Dominik, Stenzel, Werner, Niesner, Raluca A., Hauser, Anja E., Paul, Friedemann, Radbruch, Helena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119413/ https://www.ncbi.nlm.nih.gov/pubmed/33986412 http://dx.doi.org/10.1038/s41598-021-89786-0 |
Ejemplares similares
-
Low-Density Granulocytes Are a Novel Immunopathological Feature in Both Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
por: Ostendorf, Lennard, et al.
Publicado: (2019) -
Phasor-Based Endogenous NAD(P)H Fluorescence Lifetime Imaging Unravels Specific Enzymatic Activity of Neutrophil Granulocytes Preceding NETosis
por: Leben, Ruth, et al.
Publicado: (2018) -
Impaired motion perception is associated with functional and
structural visual pathway damage in multiple sclerosis and neuromyelitis optica
spectrum disorders
por: Ayadi, Noah, et al.
Publicado: (2021) -
Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study
por: Sperber, Pia S., et al.
Publicado: (2022) -
Structure–function correlates of vision loss in neuromyelitis optica spectrum disorders
por: Gigengack, Norman K., et al.
Publicado: (2022)